Treating diabetes today: a matter of selectivity of sulphonylureas
- PMID: 22118705
- DOI: 10.1111/j.1463-1326.2011.01507.x
Treating diabetes today: a matter of selectivity of sulphonylureas
Abstract
It is well known that sulphonylureas (SUs), commonly used in the treatment of type 2 diabetes mellitus, stimulate insulin secretion by closing ATP-sensitive K(+) (K(ATP) ) channels in pancreatic β-cells by binding to the SU receptor SUR1. SUs are now known also to activate cAMP sensor Epac2 (cAMP-GEFII) to Rap1 signalling, which promotes insulin granule exocytosis. For SUs to exert their full effects in insulin secretion, they are required to activate Epac2 as well as to inhibit the β-cell K(ATP) channels. As Epac2 is also necessary for potentiation of glucose-induced insulin secretion by cAMP-increasing agents, such as incretin, Epac2 is a target of both cAMP and SUs. The distinct effects of various SUs appear to be because of their different actions on Epac2/Rap1 signalling as well as K(ATP) channels. Differently from other SUs, gliclazide is unique in that it is specific for β-cell K(ATP) channel and does not activate Epac2.
© 2011 Blackwell Publishing Ltd.
Similar articles
-
cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells.J Physiol. 2006 Jun 15;573(Pt 3):595-609. doi: 10.1113/jphysiol.2006.107391. Epub 2006 Apr 13. J Physiol. 2006. PMID: 16613879 Free PMC article.
-
Shortcomings of current models of glucose-induced insulin secretion.Diabetes Obes Metab. 2009 Nov;11 Suppl 4:168-79. doi: 10.1111/j.1463-1326.2009.01109.x. Diabetes Obes Metab. 2009. PMID: 19817799 Review.
-
Epac2: a sulfonylurea receptor?Biochem Soc Trans. 2012 Feb;40(1):6-10. doi: 10.1042/BST20110640. Biochem Soc Trans. 2012. PMID: 22260657
-
[Pharmacogenetics of insulin secretagogue antidiabetics].Orv Hetil. 2011 Oct 9;152(41):1651-60. doi: 10.1556/OH.2011.29175. Orv Hetil. 2011. PMID: 21959939 Review. Hungarian.
-
Cooperation between cAMP signalling and sulfonylurea in insulin secretion.Diabetes Obes Metab. 2014 Sep;16 Suppl 1:118-25. doi: 10.1111/dom.12343. Diabetes Obes Metab. 2014. PMID: 25200305 Review.
Cited by
-
Modulated Protein Binding Ability of Anti-Diabetic Drugs in Presence of Monodispersed Gold Nanoparticles and its Inhibitory Potential towards Advanced Glycated End (AGE) Product Formation.J Fluoresc. 2020 Jan;30(1):193-204. doi: 10.1007/s10895-019-02485-y. Epub 2020 Jan 10. J Fluoresc. 2020. PMID: 31925653
-
Effect of methanolic extract of Tetrapleura tetraptera (Schum and Thonn) Taub leaves on hyperglycemia and indices of diabetic complications in alloxan-induced diabetic rats.Asian Pac J Trop Biomed. 2014 Apr;4(4):272-8. doi: 10.12980/APJTB.4.2014C73. Asian Pac J Trop Biomed. 2014. PMID: 25182550 Free PMC article.
-
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors.Int J Mol Sci. 2021 Feb 7;22(4):1680. doi: 10.3390/ijms22041680. Int J Mol Sci. 2021. PMID: 33562380 Free PMC article. Review.
-
Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.Diabetes Metab Res Rev. 2021 Oct;37(7):e3434. doi: 10.1002/dmrr.3434. Epub 2021 Feb 7. Diabetes Metab Res Rev. 2021. PMID: 33900667 Free PMC article. Review.
-
2,2-Dimethyl-3,4-dihydro-2H-1,4-benzoxazines as isosteres of 2,2-dimethylchromans acting as inhibitors of insulin release and vascular smooth muscle relaxants.Medchemcomm. 2019 Feb 12;10(3):431-438. doi: 10.1039/c8md00593a. eCollection 2019 Mar 1. Medchemcomm. 2019. PMID: 31015906 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
